Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
Roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease versus comparators
In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo
Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no increased risk of MACE or all-cause mortality versus epoetin alfa
In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa
New data from the Phase III DAPA-HF trial showed FARXIGA reduced the worsening of heart failure or cardiovascular death in HFrEF patients with and without chronic kidney disease
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular (CV) death or worsening of HF in patients with HF with reduced ejection fraction (HFrEF), irrespective of the presence of chronic kidney disease (CKD).
Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in Phase III OLYMPUS and ROCKIES trials
OLYMPUS demonstrated a mean increase of 1.75g/dL averaged over weeks 28 to 52, compared to 0.40g/dL with placebo
ROCKIES demonstrated a mean increase of 0.77g/dL averaged over weeks 28 to 52, compared to 0.68g/dL with epoetin alfa
CALQUENCE® data to show improved progression-free survival in Phase III front-line chronic lymphocytic leukemia at ASH 2019 Annual Meeting
Robust early-stage pipeline advancements and presentations across multiple scientific platforms demonstrate potential to improve treatment outcomes in blood cancers with high unmet need
Latest AZ&You Blog Articles
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.